PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results
PDS Biotechnology Corporation (Nasdaq: PDSB) will announce its third-quarter financial results on November 14, 2022, prior to market opening.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PDS Biotechnology Corporation (Nasdaq: PDSB) will announce its third-quarter financial results on November 14, 2022, prior to market opening. A conference call will follow to discuss the results and provide a business update. The company focuses on developing immunotherapies targeting cancer and infectious diseases, utilizing its proprietary Versamune® and Infectimune™ technologies. The lead candidate, PDS0101, has shown promise in clinical trials for HPV-positive cancers.
Details
News Market Reaction – PDSB
The recorded move for PDSB in the trading session of this news was -2.60%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FLORHAM PARK, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that the Company will release financial results for the third quarter of 2022 on Monday, November 14, 2022, before the market opens. Following the release, management will host a conference call to review the financial results and provide a business update.
| Monday, November 14, 2022, 8:00 AM EST | ||
| Domestic: | 877-407-3088 | |
| International: | 201-389-0927 | |
| Conference ID: 13733006 | ||
| Webcast: PDS Biotech Earnings Webcast |
After the live webcast, the event will be archived on PDS Biotech’s website for six months.
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune® and Infectimune™ T cell-activating technology platforms. We believe our targeted Versamune® based candidates have the potential to overcome the limitations of current immunotherapy by inducing large quantities of high-quality, potent polyfunctional tumor specific CD4+ helper and CD8+ killer T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the potential to reduce tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV-positive cancers in multiple Phase 2 clinical trials. Our Infectimune™ based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Versamune® is a registered trademark and Infectimune™ is a trademark of PDS Biotechnology.
Investor Contacts:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
drandolph@pdsbiotech.com
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
pdsb@cg.capital
Media:
Dave Schemelia
Tiberend Strategic Advisors, Inc.
Phone: +1 (609) 468-9325
dschemelia@tiberend.com
Bill Borden
Tiberend Strategic Advisors, Inc.
Phone : +1 (732) 910-1620
bborden@tiberend.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.